Home » Newsletters » BioWorld Science

BioWorld Science

Feb. 18, 2009

View Archived Issues

TriN Pharma scientists claim antitumoral triazine compounds and their use in cancer therapy

Merck KGaA presents Met kinase inhibitors for cancer

New CB2 agonists discovered at Bristol-Myers Squibb

Otsuka claims new neuroprotectants and their use in Parkinson's disease

CNRS patent covers new anticancer agents

Intravaginal C5A application protects mice from vaginal HIV-1 transmission

New HIV-1 drug displays excellent in vitro potency against NNRTI-resistant viruses

Sanofi pasteur initiates phase IIb clinical trial of C. difficile vaccine

Chi-Med completes enrollment in phase II trial of HMPL-004 in Crohn's disease

Eisai reviews latest developments from third quarter

Phase I NKTR-105 study starts dosing in patients with refractory solid tumors

GSK initiates phase III program for novel type 2 diabetes drug, Syncria

PRIMA-1 suppresses progestin-induced tumor growth in rats

Clofazimine acts on target implicated in autoimmune diseases

Chelsea reports findings from open-label pivotal phase III droxidopa trials

Galantamine beneficial in elderly patients with severe Alzheimer's disease

Cubist commences phase I CB-182804 trial in humans

Depomed initiates phase I DM-1992 trial in Parkinson's disease

Lux Biosciences initiates LX-214 study for dry eye syndrome

BioTie initiates E.U. clinical trial of VAP-1 monoclonal antibody BTT-1023 in RA

Vion files NDA with FDA for oncology therapeutic Onrigin in AML

Flamel and Merck Serono sign license agreement to apply Medusa technology to therapeutic protein

Sequella receives SBIR grant from NIH for preclinical development of TB drug SQ-609

Pixantrone decreases time to complete remission in non-Hodgkin's lymphoma

Chugai enters license agreement with Romark for nitazoxanide in Japan

Cipher receives tentative FDA approval for extended-release tramadol

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 3, 2026.
ASCO 2026: A revolution in pancreatic cancer
BioWorld
At the 2026 American Society of Clinical Oncology (ASCO) Annual Meeting, Revolution Medicines Inc. followed up its stellar top-line data with the details from the...
News in brief
BioWorld Asia
BioWorld Asia briefs for June 2, 2026
EASL 2026: Emerging liver disease targets to watch
BioWorld
At the recently concluded European Association for the Study of the Liver meeting, presentations underscored how increasingly granular insights into liver...
ASCO 2026: PD-(L)1 x VEGF bispecifics fight it out
BioWorld
Multiple companies are chasing Akeso Inc. and Summit Therapeutics Inc. in the battle to potentially dethrone Keytruda (pembrolizumab, Merck & Co. Inc.) as the top...